HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.